Sunday, October 11, 2026

Pinduoduo Inc. Stock Went Down By Over 3% On Tuesday

November 17, 2020

Shares of Pinduoduo Inc. slid 3.26% to $137.4 at 16:11 UTC on Tuesday, while the Nasdaq Stock Market is up by 0.04% to $11895.2 at 15:27 UTC . This was the stock's two consecutive sessions of gains. Pinduoduo Inc. closed at $134.21, above its 52-week high of $116.79. Pinduoduo Inc.'s sales growth is 73.9% for the present quarter and 74.9% for the next. The company's growth estimates for the present quarter and the next are 15% and 90%, respectively. Pinduoduo Inc.'s stock is valued at $137.4, way above its 52 Week High of 116.79. Pinduoduo Inc.'s value is way higher than its 50 day moving average of $84.53. Pinduoduo Inc.'s value is way higher than its 200 day moving average of $78.68.

Tags

Stock Market Stock Wall Street Stock Price Stock Market Now NASDAQ Market Session Pinduoduo Inc.PDD IXIC The Nasdaq Stock Market

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed

Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,366 source documents archived

Query this data → isubstrate.com

Categories

Tags